Notice of Appeal
Cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046]
The appeal hearing will hear appeals against the Final Draft Guidance for the above technology by the following organisations:
- Ipsen
The appeal panel will convene on Tuesday 19 September at 10.00am via Zoom to hear oral representations from the appellants.
This page was last updated: